Our findings suggest that ufmylation on UFBP1 alleviates NAFLD-related symptoms, including obesity, hepatic steatosis, insulin resistance, dyslipidemia and liver damage (Figs. 3–5). Here, DDRGK1 is linked to fatty liver disease.